Skip to main content
Premium Trial:

Request an Annual Quote

Silence Therapeutics Names New CEO; Alnylam Taps Legal Chief; Definiens Hires North American Head; and Others

NEW YORK (GenomeWeb News) — Karen Remington has been named director of the Center for Bioinformatics and Computational Biology at the National Institute of General Medical Sciences.
Remington previously was project manager for the National Ecological Observatory Network, was vice president of bioinformatics research at the J. Craig Venter Institute, and was involved in computational biology at Celera Genomics.

Applied Bioystems has promoted Mark Stevenson from president of the Molecular and Cell Division to executive vice president of the company. ABI said the Molecular and Cell Division will also be split into two groups: MCB Systems and MCB Consumables.

Silence Therapeutics has named Jeffrey Vick CEO. Vick was in senior management at DepoTech, was vice president of corporate development for Cytoyia, vice president of business development at Genset, and vice president of corporate development and intellectual property at Centelion.

Mark Crane has been appointed vice president of business development and marketing at Ricerca Biosciences. Crane formerly was employed by Bridge Pharmaceutical, Quest Pharmaceutical, and MDS Pharma Services.

GeneNews has tapped Bernard Levin, former chair of the National Colorectal Cancer Roundtable, to chair its colorectal cancer clinical advisory board. Levin currently is vice president and head of the Division of Cancer Prevention and Population Sciences at the University of Texas M. D. Anderson Cancer Center.

Alnylam has named Philip Chase to be vice president of legal affairs, Eric Raichle vice president of human resources, and Jason Rhodes vice president of business development.
Chase has served at ReneMed Biologics and Transkaryotic Therapies; Raichle has experience working with Wyeth and the biotech venture capital branch of Fidelity Investments.

The Biomarkers Consortium this week said its membership now includes more than 30 total organizations, including founding and contributing members. The consortium aims to “harmonize approaches to identifying viable biomarkers, verify their individual value, and formalize their use in research and regulatory approval.” 
The consortium’s founding members include the Foundation for the National Institutes of Health, the NIH, the US Food and Drug Administration, and the Pharmaceutical Research and Manufacturers of America.
Contributing members include: the Academy of Molecular Imaging; the Advanced Medical Technology Association; the Alzheimer’s Association; the American Association for Cancer Research; the American Cancer Society; the American College of Neuropsychopharmacology; the American Society of Clinical Oncology; the Association of Clinical Research Organizations; AstraZeneca; BG Medicine; the Biotechnology Industry Organization; Boehringer-Ingelheim Pharmaceuticals; Bristol-Myers Squibb; EMD Serono; the Michael J. Fox Foundation for Parkinson’s Research; GlaxoSmithKline; GVK BIOSciences; Johnson & Johnson, the Kidney Cancer Association; The Leukemia & Lymphoma Society; Eli Lilly; Luminex; Merck; Novartis; Novo Nordisk; Pfizer; the Pharmaceutical Research and Manufacturers of America; the Radiological Society of North America; Roche; and the Society of Nuclear Medicine.       

Genstruct has named Christopher Thomajan chief financial officer. Thomajan has worked in financial management posts at Asurion, Celadon Science, and American’s Growth Capital.

Definiens has promoted Greg Calaman to be vice president of North American operations. Calaman came to Definiens from Pfizer, where he was on the IT leadership team, and he was involved in healthcare technology prior to that.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.